View of Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis

Return to Article Details Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis Download Download PDF